Embecta Slips To Loss In Q4
(RTTNews) - Diabetes management company Embecta Corp. (EMBC), which listed on the NASDAQ on Apr.1, 2022 after spinning-off from medical technology company Becton, Dickinson and Co. (BDX), announced Tuesday a net loss of $17.2 million or $0.30 per share, compared to net income of $97.1 million or $1.70 per share in the prior-year quarter.
Revenues for the quarter decreased 8.7 percent to $274.6 million from $300.8 million in the same quarter last year. It was also down 4.2 percent on a constant currency basis.
On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.66 per share on revenues of $261.01 million for the quarter. Analysts' estimates typically exclude special items.
Looking ahead to fiscal 2023, the company now projects adjusted earnings in a range of $1.75 to $2.00 per share on revenues between $1.050 billion and $1.073 billion. The Street is looking for earnings of $3.11 per share on revenues of 1.11 billion for the year.
The Company's Board of Directors also declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock, payable on January 11, 2023 to stockholders of record at the close of business on December 30, 2022.
Commodity Currencies Advance After Trump's Tariff Delay
Canadian Dollar Advances Against Majors
European Shares Seen Opening Up After Trump's Tariff Delay
NZ Dollar Advances Against Most Majors
Australian Dollar Rises Against Majors
Sensex, Nifty Open Higher As Tariff Worries Ease
Asian Markets A Sea Of Green
